Latest Press Releases

Looking for the latest news on the products and services you patronize? Presswire is your go-to website. Presswire is the leading online news and press release distribution service. Used by thousands of organizations of every size to get better visibility, improve their ranks on the search engines, drive traffic to their website, and deliver the latest news to their respective target audiences. Presswire's press release distribution services go to various media outlets in our media contacts database, keeping everyone in-the-know informed. Do you have a news story to feature? Send and create your stories or product and service news to Presswire, but filling out the form here.

ProMIS Neurosciences Announces Abstracts Accepted for Presentation at the American Academy of Neurology 2023 Annual Meeting

 

[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Massachusetts – March 13, 2023 – ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced an oral presentation and two onsite poster presentations at the upcoming American Academy of Neurology (AAN) Annual Meeting, which will be held on April 22-27, 2023 in Boston, MA. The presentations highlight ProMIS’ broad pipeline of next-generation neurodegenerative disease therapeutics, including data that further characterize lead drug AD candidate, PMN310, as well as preclinical optimization studies of an Alzheimer’s vaccine and data supporting RACK1 as a potential target in amyotrophic lateral sclerosis (ALS).

ProMIS Neurosciences to Present New Preclinical Data for PMN310 at AD/PD 2023

 

[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Massachusetts – March 13, 2023 – ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that new preclinical data for ProMIS’ lead candidate for AD, PMN310, will be presented as a virtual short oral poster presentation at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2023) to be held on March 28-April 1, 2023 virtually and in Gothenburg, Sweden.

Leading Tokenization Firm DigiShares Introduces Three New Solutions

 

[PRESSWIRE] Denmark – 09.03.23 -- DigiShares, a global provider of infrastructure for tokenization of real-world assets, has recently introduced three new configurations of its market leading platform, to cater for three different market segments. This enables DigiShares to support the main three tokenization use cases, crypto-settled, fiat-settled, and internally settled. Each configuration is optimized for full automation and ease of use.

ProMIS Neurosciences Announces Full Year 2022 Financial Results and Recent Highlights

 

[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Massachusetts – March 8, 2023 – ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced its full year 2022 financial results and recent highlights.

Promis Neurosciences to Present at the Oppenheimer 33rd Annual Healthcare Conference

 

[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Massachusetts – March 8, 2023 – ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that Gail Farfel, Ph.D., Chief Executive Officer, will present at the upcoming Oppenheimer 33rd Annual Conference on Monday, March 13, 2023 at 12:30 p.m. ET.

1

Orit Fuchs: From Advertising to Artistry

 

[PRESSWIRE] Israel – 07.03.23 -- Orit Fuchs is a world-renowned artist, known for her unique and personal works that focus on color and texture. Her journey to becoming an artist started in the world of advertising, where she worked as an art director in the largest advertising agencies in Israel. While she loved the excitement of the industry and the creative process, she decided to leave advertising to focus on motherhood after giving birth to her first child.

Quorum Unveils Bolstered Product Offering Tailored for EU Affairs Professionals

 

[PRESSWIRE] Brussels – 06.03.23 -- With Quorum Communications and powerful legislative tracking all in one place, you can get your story to the press and to policymakers at the same time.

1

Finance firms spend £22K per hour fighting fraud and financial crime

[PRESSWIRE] London, UK - 06.03.23 -- UK financial services firms such as banks are spending around £194.6million per year protecting themselves and their customers against fraud and financial crime.

1

Cubic Telecom Announces World First with new MNO adaptable VoLTE encryption algorithm

[PRESSWIRE] Ireland - 06.03.23 -- The new capability allows complete flexibility for Cubic Telecom to build global VoLTE roaming solution to every market worldwide

1

世界最高齢者、116歳を迎える: アメリカ生まれのスペイン人女性、マリア・ブラニャス・モレラさんが、稀有なマイルストーンを達成

 

[PRESSWIRE] スペイン・カタルーニャ州オロット - 世界最高齢者であるマリア・ブラニャス・モレラさんが、116歳になられました。今日まで、116歳という年齢を確認できたのは史上25人しかいませんでした。ブラニャス・モレラさんは、今年初め118歳のフランスのルシール・ランドンさんの死去に伴い、世界最高齢者の称号を手に入れました。